Journal
VIRUSES-BASEL
Volume 13, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/v13071214
Keywords
respiratory syncytial virus; G protein; pathogenesis; vaccines; treatment
Categories
Funding
- NIH [2U19AI095227, HHSN272201300018I]
Ask authors/readers for more resources
Respiratory syncytial virus (RSV) causes serious respiratory infections in young children and the elderly. The G protein, alongside the F protein, is a key target for vaccine and antiviral drug development due to its role in cellular infection and modulation of immune responses.
Respiratory syncytial virus (RSV) is a major cause of serious lower respiratory tract infections in children < 5 years of age worldwide and repeated infections throughout life leading to serious disease in the elderly and persons with compromised immune, cardiac, and pulmonary systems. The disease burden has made it a high priority for vaccine and antiviral drug development but without success except for immune prophylaxis for certain young infants. Two RSV proteins are associated with protection, F and G, and F is most often pursued for vaccine and antiviral drug development. Several features of the G protein suggest it could also be an important to vaccine or antiviral drug target design. We review features of G that effect biology of infection, the host immune response, and disease associated with infection. Though it is not clear how to fit these together into an integrated picture, it is clear that G mediates cell surface binding and facilitates cellular infection, modulates host responses that affect both immunity and disease, and its CX3C aa motif contributes to many of these effects. These features of G and the ability to block the effects with antibody, suggest G has substantial potential in vaccine and antiviral drug design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available